The FDA granted approval to lecanemab, a new Alzheimer's treatment that showed a 35% slowing of cognitive decline in early-stage patients in a landmark 18-month trial.

Researchers reported that 42 out of 42 patients in a phase 3 clinical trial of a CRISPR-based gene therapy are free of sickle cell disease crises, with the longest follow-up now at five years.